Chapter 56: Male Reproductive Health Drug Therapy

Male Reproductive Health Drug Therapy details the three essential reproductive processes: spermatogenesis, the regulation of sexual function, and the mechanics of sexual intercourse, including the five phases of the sexual response cycle. A significant portion of the discussion centers on the hypothalamic-pituitary-gonadal axis, explaining how the coordination of gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone maintains testosterone levels and sperm production. The text explores various disorders such as primary and secondary hypogonadism, delayed puberty, and benign prostatic hyperplasia (BPH), alongside their respective pharmacological treatments. Androgen replacement therapy is examined extensively, covering the use of testosterone cypionate and other formulations, their delivery methods like transdermal patches and gels, and the critical safety precautions required to prevent secondary exposure in women and children. Additionally, the chapter addresses the management of erectile dysfunction using phosphodiesterase-5 inhibitors, highlighting vital drug interactions with nitrates that can lead to severe hypotension. Beyond therapeutic use, it cautions against the risks associated with anabolic steroid abuse and details the role of antiandrogens in treating prostate cancer and BPH. Integrated throughout are nursing interventions, emphasizing the importance of baseline assessments, monitoring for adverse effects like priapism or hypercalcemia, and educating patients on medication adherence and lifestyle adjustments. This comprehensive overview bridges the gap between biological theory and clinical practice, ensuring a thorough understanding of male reproductive wellness and patient-centered pharmacological care.